181 related articles for article (PubMed ID: 23011899)
1. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development.
Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC
Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899
[TBL] [Abstract][Full Text] [Related]
2. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
3. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
4. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
Illingworth CJ; Loenarz C; Schofield CJ; Domene C
Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530
[TBL] [Abstract][Full Text] [Related]
5. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway?
Minervini G; Masiero A; Moro S; Tosatto SC
FEBS Lett; 2013 Sep; 587(18):2996-3001. PubMed ID: 23886708
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the Binding Interaction between the Hypoxia-Inducible Transcription Factor and the von Hippel-Lindau Suppressor.
Domene C; Jorgensen C; Vanommeslaeghe K; Schofield CJ; MacKerell A
J Chem Theory Comput; 2015 Aug; 11(8):3946-54. PubMed ID: 26574473
[TBL] [Abstract][Full Text] [Related]
8. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
9. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
10. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Liu J; Nussinov R
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
[TBL] [Abstract][Full Text] [Related]
11. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
12. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
13. Insights into the molecular features of the von Hippel-Lindau-like protein.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
Amino Acids; 2019 Nov; 51(10-12):1461-1474. PubMed ID: 31485743
[TBL] [Abstract][Full Text] [Related]
14. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
15. von Hippel-Lindau β-domain-luciferase fusion protein as a bioluminescent hydroxyproline sensor for a hypoxia-inducible factor prolyl hydroxylase assay.
Hong S; Yum S; Ha NC; Jung Y
Anal Biochem; 2010 Dec; 407(2):220-5. PubMed ID: 20705044
[TBL] [Abstract][Full Text] [Related]
16. Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors.
Minervini G; Lopreiato R; Bortolotto R; Falconieri A; Sartori G; Tosatto SCE
Sci Rep; 2017 Apr; 7():46562. PubMed ID: 28425505
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
18. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
19. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
20. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
